Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

'Tactical approval delays' steer Eisai beyond Europe

This article was originally published in Scrip

Executive Summary

Much has been made of the opportunities for rapid growth in emerging markets including those of central and eastern Europe and the Middle East. Companies are being tempted there not just by the carrot of increased health spending in those markets, but by the stick of the increasingly hostile environment they are experiencing in established European markets. Eisai is a case in point, with its EU chief Gary Hendler recently seeing his remit expanded to a broader focus on the EMEA (Europe, Middle East and Africa).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register